Aurobac Therapeutics

France · Founded 2022 · $43.2M raised

Founded
2022
Business Model
B2B
Total Funding
$43.2M
Last Round
$43.2M Corporate RoundJul 2022
Rounds
1

About

AUROBAC THERAPEUTICS is a biopharmaceutical company founded in 2022 by Boehringer Ingelheim, Evotec and bioMerieux, developing patient- and pathogen-targeted therapies to combat serious bacterial infections and Antimicrobial Resistance (AMR) in acute hospital settings, including hospital-acquired pneumonia and sepsis. Its diagnostic-driven R&D strategy spans research through commercialization, with entities in France, the UK, and the US.

Summary

Aurobac Therapeutics is a Biotech company based in France, founded in 2022. It has raised $43.2M in total across 1 round, most recently a $43.2M Corporate Round in Jul 2022. Investors include Boehringer Ingelheim Venture Fund, Evotec and bioMerieux.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Corporate RoundCorporate RoundJul 2022
$43.2M

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Aurobac Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/aurobac-therapeutics"><img src="https://indexed.vc/api/badge/company/aurobac-therapeutics" alt="Aurobac Therapeutics on Indexed.vc" width="260" height="76" /></a>